Stress symptoms induced by repeated morphine withdrawal in comparison to other chronic stress models in mice

Neuroendocrinology

Volumn 81, Issue 3, 2005, Pages 205-215

  Zelena, Dóra ^a   Barna, István ^a   Mlynarik, Martin ^a,b   Gupta, O P ^a,c   Jezova, Daniela ^a,b   Makara, Gábor B ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^c Minority/Remedial Coaching Centre   (India)

Author keywords

Adrenal steroids; Corticotropin; Diabetes mellitus; Mice; Opiate; Opiate antagonists; Streptozotocin; Stress

Indexed keywords

MORPHINE; NALOXONE; STREPTOZOCIN;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXPOSURE; FOLLOW UP; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMOBILIZATION STRESS; INVOLUTION; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; STRESS; THYMUS; TIME; TREATMENT OUTCOME; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ANIMALS; CHRONIC DISEASE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; MALE; MICE; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; RESTRAINT, PHYSICAL; SOCIAL ENVIRONMENT; STRESS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 23844498807     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087034     Document Type: Article

References (49)

1. Goeders NE: The impact of stress on addiction. Eut Neuropsychopharmacol 2003;13:435-441.
2. Pedersen SS, Denollet J: Type D personality, cardiac events, and impaired quality of life: A review. Eur J Cardiovasc Prev Rehabil 2003;10:241-248.
3. Rosmond R: Stress induced disturbances of the HPA axis: a pathway to type 2 diabetes? Med Sci Monit 2003;9:RA35-39.
4. Charney DS, Manji HK: Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE. 2004;2004(225):re5.
5. Dhabhar FS: Acute stress enhances while chronic stress suppresses skin immunity. The role of stress hormones and leukocyte trafficking. Ann NY Acad Sci 2000;917:876-893.
6. Claes SJ: Corticotropin-releasing hormone (CRH) in psychiatry: from stress to psychopathology. Ann Med 2004;36:50-61.
7. Panagiotaropoulos T, Papaioannou A, Pondiki S, Prokopiou A, Stylianopoulou F, Gerozissis K: Effect of neonatal handling and sex on basal and chronic stress-induced corticosterone and leptin secretion. Neuroendocrinology 2004;79:109-118.
8. Willner P: Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997;134:319-329.
9. Duncko R, Kiss A, Skultetyova I, Rusnak M, Ježová D: Corticotropin-releasing hormone mRNA levels in response to chronic mild stress rise in male but not in female rats while tyrosine hydroxylase mRNA levels decrease in both sexes. Psychoneuroendocrinology 2001; 26:77-89.
10. Chan O, Inouye K, Riddell MC, Vranic M, Matthews SG: Diabetes and the hypothalamopituitary-adrenal (HPA) axis. Minerva Endocrinol 2003;28:87-102.
11. Rabadan-Diehl C, Kiss A, Camacho C, Aguilera G: Regulation of messenger ribonucleic acid for corticotropin releasing hormone receptor in the pituitary during stress. Endocrinology 1996;137:3808-3814.
12. Piotrowski P: Are experimental models useful for analysis of pathogenesis of changes in central nervous system in human diabetes? Folia Neuropathol 2003;41:167-174.
13. De Nicola AF, Fridman O, Del Castillo EJ, Foglia VG: The influence of streptozotocin diabetes on adrenal function in male rats. Horm Metab Res 1976;8:388-392.
14. Chan O, Chan S, Inouye K, Shum K, Matthews SG, Vranic M: Diabetes impairs hypothalamopituitary-adrenal (HPA) responses to hypoglycemia, and insulin treatment normalizes HPA but not epinephrine responses. Diabetes 2002;51:1681-1689.
15. Antelman SM, Eichler A.J, Black C.A, Kocan D: Interchangeability of stress and amphetamine in sensitization. Science 1980;207:329-331.
16. Deroche V, Piazza PV, Casolini P, Le Moal M, Simon H: Sensitization to the psychomotor effects of amphetamine and morphine induced by food restriction depends on corticosterone secretion. Brain Res 1993;611:352-356.
17. Breese GR, Knapp DJ, Overstreet DH: Stress Sensitization of ethanol withdrawal-induced reduction in social interaction: inhibition by CRF-1 and benzodiazepine receptor antagonists and a 5-HT(1A)-receptor agonist. Neuropsychopharmacology 2004;29:470-482.
18. Haracz JL, Bloom AS, Wang RI, Tseng LF: Effect of intraventricular beta-endorphin and morphine on hypothalamic-pituitary-adrenal activity and the release of pituitary beta-endorphin. Neuroendocrinology 1981;33:170-175.
19. Ježová D, Vigas M, Jurcovicova J: ACTH and corticosterone response to naloxone and morphine in normal, hypophysectomized and dexamethasone-treated rats. Life Sci 1982;31:307-314.
20. Houshyar H, Cooper ZD, Woods JH: Paradoxical effects of chronic morphine treatment on the temperature and pituitary-adrenal responses to acute restraint stress: a chronic stress paradigm. J Neuroendocrinol 2001;13: 862-874.
21. Houshyar H, Galigniana MD, Pratt WB, Woods JH: Differential responsivity of the hypothalamic-pituitary-adrenal axis to glucocorticoid negative-feedback and corticotropin releasing hormone in rats undergoing morphine withdrawal: possible mechanisms involved in facilitated and attenuated stress responses. J Neuroendocrinol 2001;10:875-886.
22. Houshyar H, Gomez F, Manalo S, Bhargava A, Dallman MF: Intermittent morphine administration induces dependence and is a chronic stressor in rats. Neuropsychopharmacology 2003;11:1960-1972.
23. Grootendorst J, de Kloet ER, Dalm S, Oitzl MS: Reversal of cognitive deficit of apolipoprotein E knockout mice after repeated exposure to a common environmental experience. Neuroscience 2001;108:237-247.
24. Makimura H, Mizuno TM, Isoda F, Beasley J, Silverstein JH, Mobbs CV: Role of glucocorticoids in mediating effects of fasting and diabetes on hypothalamic gene expression. BMC Physiol 2003;3:5.
25. Meehan WP, Leedom LJ, Nagayama T, Zeidler A: Agonistic behavior patterns in mice with streptozotocin-induced diabetes mellitus. Physiol Behav 1986;38:301-306.
26. Miyata S, Hirano S, Kamei J: Diabetes attenuates the antidepressant-like effect mediated by the activation of 5-HT1A receptor in the mouse tail suspension test. Neuropsychopharmacology 2004;29:461-469.
27. Dupouy JP, Chatelain A, Boudouresque F, Conte-Devolx B, Oliver C: Effects of chronic maternal dexamethasone treatment on the hormones of the hypothalamo-pituitary-adrenal axis in the rat fetus. Biol Neonate 1987;52:216-222.
28. Nicholson S, Campbell E, Torrellas A, Beckford U, Altaher R, Sandford R, Scraggs R, Gillham B, Jones M: Recovery of the hypothalamo-pituitary- adrenocortical axis in the rat after long-term dexamethasone treatment. Neuroendocrinology 1984;39:343-349.
29. Zelena D, Makara GB, Ježová D: Simultaneous blockade of two glutamate receptor subtypes (NMDA and AMPA) results in stressor-specific inhibition of prolactin and corticotropin release. Neuroendocrinology 1999;69:316-323.
30. Zelena D, Mergl Z, Foldes A, Kovacs KJ, Toth Z, Makara GB: Role of hypothalamic inputs in maintaining pituitary-adrenal responsiveness in repeated restraint. Am J Physiol 2003;285:E1110-E1117.
31. Simmons A: Complete protocol for in situ hybridization of messenger RNAs in brain and other tissues with radiolabeled single-stranded RNA probes. J Histotechnol 1989;12:169-181.
32. Morley JE: The endocrinology of the opiates and opioid peptides. Metabolism 1981;30:195-209.
33. Alcaraz C, Vargas ML, Milanes MV: Chronic naloxone-induced supersensitivity affects neither tolerance to nor physical dependence on morphine at hypothalamus-pituitary-adrenocortical axis. Neuropeptides 1996;30:29-36.
34. Buckingham JC, Cooper TA: Differences in hypothalamo-pituitary- adrenocortical activity in the rat after acute and prolonged treatment with morphine. Neuroendocrinology 1984;38:411-417.
35. Ježová D, Mlynarik M, Zelena D, Makara GB: Behavioral sensitization to intermittent morphine in mice is accompanied by reduced adrenocorticotropin but not corticosterone responses. Brain Res. 2004;1021:63-68.
36. Avila AH, Alonzo NC, Bayer BM: Immune cell activity during the initial stages of withdrawal from chronic exposure to cocaine or morphine. J Neuroimmunol 2004;147:109-113.
37. Lightman SL, Young WS 3rd: Corticotrophin-releasing factor, vasopressin and pro-opiomelanocortin mRNA responses to stress and opiates in the rat. J Physiol 1988;403:511-523.
38. Höllt V, Haarmann I: Differential alterations by chronic treatment with morphine of proopiomelanocortin mRNA levels in anterior as compared to intermediate pituitary lobes of rats. Neuropeptides 1985;5:481-484.
39. Ježová D, Škultétyová I: Neuroendocrine response in stress - a specific activation by individual stressors. Arch Physiol Biochem 1977;105:233-237.
40. Pacak K, Palkovits M, Kvetnansky R, Yadid G, Kopin IJ, Goldstein DS: Effects of various stressors on in vivo norepinephrine release in the hypothalamic paraventricular nucleus and on the pituitary-adrenocortical axis. Ann NY Acad Sci 1995;771:115-130.
41. Aguilera G: Regulation of pituitary ACTH secretion during chronic stress. Front Neuroend 1994;15:321-350.
42. Gibson MJ, DeNicola AF, Krieger DT: Streptozotocin-induced diabetes is associated with reduced immunoreactive beta-endorphin concentrations in neurointermediate pituitary lobe and with disrupted circadian periodicity of plasma corticosterone levels. Neuroendocrinology 1985;41:64-71.
43. Schwartz MW, Strack AM, Dallman MF: Evidence that elevated plasma corticosterone levels are the cause of reduced hypothalamic corticotrophin- releasing hormone gene expression in diabetes. Regul Pept 1997;72:105-112.
44. Scribner KA, Walker CD, Cascio CS, Dallman MF: Chronic streptozotocin diabetes in rats facilitates the acute stress response without altering pituitary or adrenal responsiveness to secretagogues. Endocrinology 1991;129:99-108.
45. Havel JP, Hahn TM, Sindelar DK, Baskin DG, Dallman MF, Weigle DS, Schwartz MW: Effects of streptozotocin-induced diabetes and insulin treatment on the hypothalamic melanocortin system and muscle uncoupling protein 3 expression in rats. Diabetes 2000;49:244-252.
46. Jones BC, Sarrieau A, Reed CL, Azar MR, Mormede P: Contribution of sex and genetics to neuroendocrine adaptation to stress in mice. Psychoneuroendocrinology 1998;23:505-517.
47. Chaouloff F, Laude D, Merino D, Serrurier B, Baudrie V, Elghozi JL: Duration of streptozotocin diabetes influences the response of hypothalamic serotonin metabolism to immobilization stress. Neuroendocrinology 1989;50:344-350.
48. Chan O, Inouye K, Vranic M, Matthews SG: Hyperactivation of the hypothalamo-pituitary-adrenocortical axis in streptozotocin-diabetes is associated with reduced stress responsiveness and decreased pituitary and adrenal sensitivity. Endocrinology 2002;143:1761-1768.
49. Droste SK, Gesing A, Ulbricht S, Muller MB, Linthorst AC, Reul JM: Effects of long-term voluntary exercise on the mouse hypothalamic-pituitary- adrenocortical axis. Endocrinology 2003;144:3012-3023.